J1597 HCPCS Level II code: Injection, glycopyrrolate (glyrx-pf), 0.1 mg
J1597 is the HCPCS code for “Injection, glycopyrrolate (glyrx-pf), 0.1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J1597Injection, glycopyrrolate (glyrx-pf), 0.1 mg
Short description: Inj glycopyrrolate, glyrx-pf
HCPCS · United States
Medicare details
The indicators CMS publishes with J1597 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jul 1, 2024
Where J1597 sits
- 1J codesDrugs administered other than orally
- 2Active code J1597Injection, glycopyrrolate (glyrx-pf), 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J1597 mean?
J1597 is the HCPCS code for “Injection, glycopyrrolate (glyrx-pf), 0.1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J1597?
CMS lists J1597’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J1597
All J codesJ1576Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mgJ1577Injection, immune globulin (qivigy), 100 mgJ1580Injection, garamycin, gentamicin, up to 80 mgJ1590Injection, gatifloxacin, 10 mgJ1595Injection, glatiramer acetate, 20 mgJ1596Injection, glycopyrrolate, 0.1 mgJ1598Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mgJ1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mgJ1600Injection, gold sodium thiomalate, up to 50 mgJ1602Injection, golimumab, 1 mg, for intravenous useJ1610Injection, glucagon hydrochloride, per 1 mgJ1611Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg